Literature DB >> 33409750

Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

Meltem Guzin Altınel1, Banu Acikalin2, Hasan Gunes2, Gokhan Demir2.   

Abstract

To determine the relation between retinal microstructural changes and the response to 577-nm subthreshold micropulse laser (SML) treatment in chronic central serous chorioretinopathy (cCSC). This retrospective study included 39 eyes of 39 patients with cCSC, treated with the 577-nm SML. The eyes were evaluated in three groups: complete remission, partial remission, and failure groups. The presence of some baseline retinal microstructural changes, thickness of the outer nuclear layer (ONL), status of the ellipsoid zone (EZ), and retinal pigment epithelium (RPE) were evaluated. The changes in central macular thickness (CMT), subretinal fluid (SRF) height, and best-corrected visual acuity (BCVA) were calculated. There were 14, 13, and 12 eyes in the complete remission, partial remission, and failure group, respectively. The baseline EZ and RPE were found intact in 71.4% and 64.3% of the eyes in the complete remission group, respectively; however, these rates were respectively 25% and 16.7% in the failure group (p < 0.05). Extrafoveal foci were present in 35.7% of the eyes in the complete remission group, but none was found in the failure group (p < 0.05). Although there was no statistically significant difference, the baseline ONL thickness was higher, and the hyperreflective dots, retinal bumps, subretinal fibrinous exudates, and PEDs were seen less in the complete remission group. The changes of the BCVA were not significant in any of the groups at the last visit (p > 0.05). The presence of baseline intact EZ and RPE, and extrafoveal foci can potentially be used as predictors of the SML treatment success in cCSC.
© 2021. The Author(s), under exclusive licence to Springer-Verlag London Ltd. part of Springer Nature.

Entities:  

Keywords:  Central serous chorioretinopathy; Ellipsoid zone; Optical coherence tomography; Subthreshold micropulse laser

Year:  2021        PMID: 33409750     DOI: 10.1007/s10103-020-03225-6

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  28 in total

1.  Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.

Authors:  Ozgur Artunay; Erdal Yuzbasioglu; Rifat Rasier; Alper Sengul; Halil Bahcecioglu
Journal:  Curr Eye Res       Date:  2010-02       Impact factor: 2.424

Review 2.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

3.  Subretinal neovascularization following argon laser photocoagulation treatment for central serous chorioretinopathy: complication or misdiagnosis?

Authors:  H Schatz; L A Yannuzzi; K A Gitter
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1977 Sep-Oct

4.  Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy.

Authors:  Andrew C T Fok; Poemen P M Chan; Dennis S C Lam; Timothy Y Y Lai
Journal:  Ophthalmic Res       Date:  2011-03-10       Impact factor: 2.892

5.  The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.

Authors:  Anna S Kitzmann; Jose S Pulido; Nancy N Diehl; David O Hodge; James P Burke
Journal:  Ophthalmology       Date:  2008-01       Impact factor: 12.079

6.  Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy.

Authors:  Yutaka Imamura; Takamitsu Fujiwara; Ron Margolis; Richard F Spaide
Journal:  Retina       Date:  2009 Nov-Dec       Impact factor: 4.256

7.  Risk factors for central serous chorioretinopathy: a case-control study.

Authors:  Robert Haimovici; Sean Koh; David R Gagnon; Todd Lehrfeld; Sarah Wellik
Journal:  Ophthalmology       Date:  2004-02       Impact factor: 12.079

8.  Chronic central serous chorioretinopathy: photodynamic therapy.

Authors:  Mehryar Taban; David S Boyer; Edgar L Thomas; Mehran Taban
Journal:  Am J Ophthalmol       Date:  2004-06       Impact factor: 5.258

9.  Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life.

Authors:  Myrte B Breukink; Alexander Jm Dingemans; Anneke I den Hollander; Jan Ee Keunen; Robert E MacLaren; Sascha Fauser; Giuseppe Querques; Carel B Hoyng; Susan M Downes; Camiel Jf Boon
Journal:  Clin Ophthalmol       Date:  2016-12-20

10.  Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy.

Authors:  Ichiro Maruko; Hideki Koizumi; Taiji Hasegawa; Hisaya Arakawa; Tomohiro Iida
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.